Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ: PRTC )

17.14 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99
Open 17.14
Bid (Size) 16.98 (1)
Ask (Size) 17.42 (1)
Prev. Close 17.14
Today's Range 17.14 - 17.14
52wk Range 13.30 - 32.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
From PureTech Health plc
Via Business Wire

Performance

YTD
-12.03%
-12.03%
1 Month
+1.89%
+1.89%
3 Month
-2.29%
-2.29%
6 Month
-16.02%
-16.02%
1 Year
-37.63%
-37.63%

More News

Read More
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
PureTech Health plc Statement Regarding Press Speculation
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
From PureTech Health plc
Via Business Wire
PureTech to Present at the Leerink Partners Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
From PureTech Health plc
Via Business Wire
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
From PureTech Health plc
Via Business Wire
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Appoints UBS as UK Corporate Broker
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From PureTech Health plc
Via Business Wire
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
From PureTech Health plc
Via Business Wire
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at CHEST 2024 Annual Meeting
From PureTech Health
Via Business Wire
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Via Benzinga
Exposures Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.